

Serrapeptase Reference

1. Kee WH, Tan SL, Lee V, Salmon YM. The treatment of breast engorgement with Serrapeptase (Danzen): a randomized double-blind controlled trial. *Singapore Med J.* 1989;30(1):48-54.
2. Mizukoshi, D. et al. A double-blind clinical study of serrapeptase in the treatment of chronic sinusitis. *Igaku Ayrni* 109:50-62.1979.
3. Carratu, L. et al. Physio-chemical and rheological research on mucolytic activity of serrapeptase in chronic broncho-pneumopathies. *Curr. Ther. Res.* 28(6):937-951. 1980.
4. Braga, P.C. et al. Effects of serrapeptase on muco-ciliary clearance in patients with chronic bronchitis. *Curr. Ther. Res.* 29(5):738-744,1981.
5. Mazzonie, A. et al. Evaluation of serrapeptase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double-blind randomized trial versus placebo. *J. int. Med. Res.* 18(5):379-388,1990.
6. Kakinumu, A. et al. Regression of fibrinolysis in scalded rats by administration of serrapeptase. *Biochem. Pharmacol.* 31:2861-2866,1982.
7. Marly, M. Enzymotherapie anti-inflammatoire a l'aide de la serrapeptase: resultats cliniques en traumatologie et en ORL. *C RTherapeut.* 3:9-19,1985.
8. Odagiri, J. et al. Clinical applications of serrapeptase in sinusitis. *Med. Consult. New Remedy* 6:201-209, 1979.
9. Yamazaki, J. et al. Anti-inflammatory activity of TSP, a protease produced by a strain of *Serratia*. *Folia Pharmacol. Japon.* 6^302-314,1967.
10. Harad~, Y. Clinical efficacy of serrapeptase on buccal swelling after radical operation for chronic sinusitis. *Igaku Ayumi* 123:768-778.1982.
11. Matsudo, A. et al. Effect of serrapeptase (Danzen) on inflammatory edema following operation for thyroid disease. *Med. Consult. New Remedy* 18:171-175, 1981.
12. Fujitani, T. et al. Effect of anti-inflammatory agent on transfer of antibiotics to the maxillary sinus mucosa in chronic sinusitis. *Otorhinolaryngol. Clin. North Am.* 66:557-565. 1976.
13. Tago. T. and Mitsui, S. Effects of serrapeptase in dissolution of sputum, especially in patients with bronchial asthma. *Jap. Clin. Exp. Med.* 49:222-228, 1972.
14. Mazzonie, A. et al. Evaluation of serrapeptase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double-blind randomized trial versus placebo. *J. int. Med. Res.* 18(5):379-388,1990.
15. Kase, Y. et al. A new method for evaluating mucolytic expectorant activity and its application. II. Application to two proteolytic enzymes, serrapeptase and seaprose. *Arzneimittelforschung* 32:374-378,1982.
16. Marriott, C. Modification of the rheological properties of mucus by drugs. *Adv. Exp. Med. Biol.* 144^75-84, 1982.
17. Majima. Y. et al. Effects of orally administered drugs on dynamic viscoelasticity of human nasal mucus. *Am. Rev. Respir. Dis.* 141:79-83.1990.
18. Miyata, K. Intestinal absorption of serrapeptase. *J ApplBiochem.* 1980:2:111-16.
19. Aso T. et al. Breast engorgement and its treatment: Clinical effects of Danzen (serrapeptase) an anti-inflammatory enzyme preparation. *The world of Obstetrics and Gynecology (Japanese).* 1981:33:371-9.

20. Esch PM, Gemgross H, Fabian A. Reduction of postoperative swelling. Objective measurement of swelling of the upper ankle joint in treatment with serrapeptase-a prospective study (German). *FortschrMed.* 1989; 107(4):67-8, 71-2.
21. Majima Y, Inagaki M, Hirata K, Takeuchi K, Morishita A, Sakakura Y. The effect of an orally administered proteolytic enzyme on the elasticity and viscosity of nasal mucus. *Arch Otorhinolaryngol.* 1988;244(6):355-9.
22. Selan L, Berlutti F, Passariello C, Comodi-Ballanti MR, Thaller MC. Proteolytic enzymes: a new treatment strategy for prosthetic infections? *Antimicrob Agents Chemother.* 1993; 37(12):2618-21.
23. Koyama A, Mori J, Tokuda H, Waku M, Anno H, Katayama T, Murakami K, Komatsu H, Hirata M, Arai T, et al. Augmentation by serrapeptase of tissue permeation by cefotiam (Japanese). *Jpn JAntibiot.* 1986; 39(3):761-7

© Naturally Healthy Publications

for more information visit: www.serrapeptase.info